Bronnen:
- Lee S, Singla A, Rulyak SJ, et al. Double-blind, randomized, placebo-controlled, crossover trial to evaluate induction of clinical response in patients with moderate-severe Crohn’s disease treated with rifaximin. P142. Presented at: Crohn’s & Colitis Congress; Jan. 19-20, 2018; Las Vegas, NV.